The group's principle activity is to develop innovative technologies for rapid and sensitive proteomics and biomarker analysis. The group also provides rapid, complete, qualitative and quantitative protein analysis. The group's solutions include biomarker discovery, population proteomics, pharmacokinetics and research programs. The group operates from United States.
Executive Information
Name
Title
Email
Dobrin Nedelkov
Interim CEO, Dir. - Research, Technology Development
